Tercica
Brisbane
About Tercica
Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 501 – 1,000
- Estimated revenue: Less than $1M
- Total funding: $148.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2007)
- Ticker: nasdaq:TRCA
- Website: ipsenus.com
- Phone: 9082756301
Industries & Categories
Biotechnology, Children, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tercica-1706614 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.